35 completed, 35 recruiting, 10 active not recruiting, 9 not yet recruiting. 100 Phase 1, 18 Phase 2.
Follow Psilocybin: new trials by email Literature Review of Psilocybin trials Research Report on Psilocybin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Psilocybin After Trauma Surgery for Pain Psilocybin (Usona Institute), Postoperative analgesia - Pain Management, Postoperative Pain | Phase 1 | Not yet recruiting | Trent Emerick | 70 | 2027-12-31 | 2026-08-06 |
| The Impact of Dose on the Impairing, Intoxicating, and Abuse-Related Effects of Psilocybin 0mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 1mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink, 5mg Psilocybin Capsule + 0.00% BAC Alcoholic Drink - Psilocybin Intoxication | Phase 1 | Not yet recruiting | Johns Hopkins University | 80 | 2027-03-01 | 2026-10-16 |
| Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder Psilocybin - Treatment Resistant Depression, Substance Use Disorders | Phase 1 / Phase 2 | Not yet recruiting | Indiana University | 50 | 2027-02-01 | 2026-10-23 |
| Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study Psilocybin, Saline Placebo, Clonidine - Well-Being, Psychological, Psychedelic Experiences | Phase 1 | Not yet recruiting | University of Wisconsin, Madison | 120 | 2027-02-01 | 2026-10-30 |
| ADEPT Psilocybin-Assisted Therapy With DBT for Borderline Personality Disorder Psilocybin, Psilocybin-Assisted Therapy With Dialectical Behavior Therapy - Borderline Personality Disorder, Borderline Personality Pathology | Phase 1 | Not yet recruiting | University of Minnesota | 18 | 2026-12-01 | 2026-09-22 |
| The Effects of Psilocybin on Social Connectedness Psilocybin, Placebo - Loneliness, Grief | Phase 1 | Not yet recruiting | Yale University | 51 | 2026-12-01 | 2026-11-12 |
| Psilocybin Effects on Healthy Aging Biomarkers and Purpose in Life Psilocybin (Usona Institute) - Aging, Longevity | Phase 1 | Recruiting | Charles Raison | 50 | 2026-11-16 | 2026-11-17 |
| Psilocybin for Chronic Pelvic Pain (CPP) in Women: A Pilot Feasibility Study Psilocybin (Usona Institute) - Chronic Pelvic Pain | Phase 1 | Recruiting | Oregon Health and Science University | 15 | 2026-11-01 | 2026-09-23 |
| Pilot Study on the Effects of Psilocybin on Belief Updating and Insight Formation Psilocybin (Usona Institute), Inactive Placebo (Usona Institute) - Phase I | Phase 1 | Recruiting | Brown University | 24 | 2026-11-01 | 2026-10-08 |
| Psilocybin for Amblyopia - Targeting Critical Periods in Humans Amblyopia Therapy, 1 mg Psilocybin, 5 mg Psilocybin - Amblyopia | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 24 | 2026-11-01 | 2026-11-05 |
| Psilocybin Efficacy With or Without Pimavanserin Pretreatment Psilocybin, Pimavanserin, Inactive Placebo - Mood (Psychological Function), Well Being | Phase 1 / Phase 2 | Recruiting | Johns Hopkins University | 20 | 2026-10-29 | 2026-11-02 |
| Psilocybin for Treatment of OCD-2 Low Dose Psilocybin, High Dose Psilocybin - Obsessive - Compulsive Disorder | Phase 1 / Phase 2 | Not yet recruiting | Francisco A Moreno | 20 | 2026-09-08 | 2026-05-12 |
| The Effects of Psilocybin in Healthy Volunteers: Psychological, Biochemical and Electrophysiological Biomarkers. Psilocybin (drug), Placebo - Healthy Participants, Placebo - Control | Phase 1 | Not yet recruiting | Gabriella Gobbi | 50 | 2026-09-01 | 2026-02-25 |
| Psilocybin as a Novel Therapy for Residual Anhedonia Psilocybin, Placebo - Anhedonia, Emotional Blunting | Phase 1 | Recruiting | NYU Langone Health | 90 | 2026-09-01 | 2026-09-15 |
| The Acute Effects of Psilocybin on Cognition, Memory, and Brain Function Placebo, Psilocybin 15mg - Healthy | Phase 1 / Phase 2 | Not yet recruiting | Manoj Doss | 48 | 2026-09-01 | 2026-06-15 |
| Psilocybin to Treat Depression in Spinal Cord Injury Psilocybin (Usona Institute) - Spinal Cord Injury, Depression - Major Depressive Disorder | Phase 1 / Phase 2 | Recruiting | James J. Peters Veterans Affairs Medical Center | 30 | 2026-08-06 | 2026-08-10 |
| A Study of Psychedelics in Healthy Older Adults With Low Well-being Psilocybin (drug), Dextromethorphan (DXM) - Anhedonia in Healthy Volunteers, Older Adults (50-90 Years) | Phase 1 | Recruiting | Jennifer Mitchell | 80 | 2026-06-01 | 2026-09-09 |
| Psilocybin Whole Mushroom for the Treatment of Obsessive-compulsive Disorder. Psilocybin 10 mg, Psilocybin 20 mg, Psilocybin 30 mg - Obsessive-Compulsive Disorder | Phase 1 | Recruiting | Francisco A Moreno | 30 | 2026-05-18 | 2026-07-23 |
| Group Psilocybin-Assisted Therapy for Post-Traumatic Stress Disorder Psilocybin - PTSD | Phase 1 | Recruiting | University of New Mexico | 36 | 2026-05-01 | 2026-05-22 |
| Safety and Tolerability Trial of Psilocybin in Healthy Older Adults Psilocybin (Usona Institute) - Healthy Volunteer, Older Adults (65-85 Years) | Phase 1 | Recruiting | University of Colorado, Denver | 40 | 2026-04-01 | 2026-09-16 |
Showing 20 of 100. Sign in to see all of them.
Depression (13) · Obsessive-Compulsive Disorder (7) · Stress Disorders, Post-Traumatic (6) · Anxiety Disorders (4) · Substance-Related Disorders (4) · Depressive Disorder, Treatment-Resistant (3) · Anhedonia (2) · Anorexia Nervosa (2) · Burnout, Psychological (2) · Chronic Pain (2) · Cluster Headache (2) · Depressive Disorder, Major (2) · Migraine Disorders (2) · Neoplasm Metastasis (2) · Neoplasms (2)
Johns Hopkins University (18) · Yale University (10) · University of Wisconsin, Madison (9) · University Hospital, Basel, Switzerland (5) · MycoMedica Life Sciences PBC (3) · Centre for Addiction and Mental Health (2) · Francisco A Moreno (2) · Gitte Moos Knudsen (2) · Imperial College London (2) · NYU Langone Health (2) · University of California, Berkeley (2) · University of California, Los Angeles (2) · University of California, San Diego (2) · University of Colorado, Denver (2) · University of Minnesota (2)
United States (73) · Canada (7) · Switzerland (6) · United Kingdom (5) · Australia (2) · Denmark (2) · Austria (1) · Brazil (1) · Israel (1)
Charles Raison, MD (4) · Benjamin Kelmendi, MD (3) · Frederick S Barrett, PhD (3) · Roland R Griffiths, Ph.D. (3) · Christopher Nicholas, PhD (2) · Francisco Moreno, MD (2) · Joshua Woolley, MD/PhD (2) · Matthias E Liechti, Prof. Dr. MD (2) · Paul Hutson, PharmD (2) · Albert Garcia-Romeu, Ph.D. (1) · Albert Garcia-Romeu, PhD (1) · Ali J. Zarrabi, MD (1) · Anahita Bassir Nia, MD (1) · Anthony Back (1) · Anthony Bossis, PhD (1)
PMID 17196053, PMID 20819978, PMID 28353056, PMID 29020861, PMID 29945469, PMID 33150319, PMID 33184743, PMID 34744825, PMID 36881769, PMID 37181888, PMID 37231080, PMID 37302533, PMID 38264632, PMID 38581739, PMID 39499526, PMID 40046861, PMID 40051480, PMID 40051582, PMID 40658345, PMID 40972137, PMID 41459830, PMID 41617652, PMID 41741501, PMID 41819589, PMID 41825921, PMID 42049943, PMID 42212900, PMID 42395285, PMID 42457666, PMID 42649324, PMID 42668404, PMID 42797541
R34AT013077 (2), K23MH122777 (1), P30CA138292 (1), R01DA066452 (1), R01MH142698 (1), R03DA042336 (1), R21DA046030 (1), R33AT012317 (1), UG3AG094957 (1)